InvestorsObserver is giving Prelude Therapeutics Inc (PRLD) an Analyst Rating Rank of 23, meaning PRLD is ranked higher by analysts than 23% of stocks. The average price target for PRLD is $6.6 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating PRLD a Buy today. Find out what this means to you and get the rest of the rankings on PRLD!